This radio-pharmacological personalization includes somatostatin receptor positivity in neuroendocrine tumors associated with the efficacy of 177Lu-DOTATATE/DOTATOC or PSMA-positive prostate cancer treated with the same radionuclide but with a different vector. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.